Recent Updates
Recently added Catalysts
CGON Positive Sentiment

CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

Monday, February 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CG Oncology, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Arthur Kuan and COO Ambaw Bellete will lead the presentation, which can be accessed via a live audio webcast. The company aims to develop innovative therapies for bladder cancer patients.
Price reaction · baseline $57.63 (2026-02-20 close) · hit pre-market · clean, no other CGON news in the window
day 0 close
+1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology is actively participating in a prominent health care conference.
  • The presentation may enhance visibility and support for their bladder cancer therapies.
  • The company is focused on improving the quality of life for bladder cancer patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 3:10 pm ET. The conference is taking place at the Boston Marriott Copley Place in Boston, MA.
Interested parties may access the live audio webcast for this conference from theInvestor Relations sectionof the company's website atwww.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit:www.cgoncology.com.

ContactsMediaSarah ConnorsVice President, Communications and Patient Advocacy, CG Oncologysarah.connors@cgoncology.com

Frequently Asked Questions

When will CG Oncology present at the conference?

CG Oncology will present on March 2, 2026, at 3:10 pm ET.

Where is the TD Cowen Conference being held?

The conference is taking place at the Boston Marriott Copley Place in Boston, MA.

How can I access the conference presentation?

The presentation can be accessed via a live audio webcast on CG Oncology's website.

What is CG Oncology focused on developing?

CG Oncology focuses on developing therapies for bladder cancer patients.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare CG Oncology bladder cancer health care conference TD Cowen immunotherapies
Last updated: Feb 23, 2026

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →